{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T15:06:15Z","timestamp":1776524775575,"version":"3.51.2"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.cpet.2022.11.001","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T07:44:28Z","timestamp":1672213468000},"page":"189-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Gastroenteropancreatic Neuroendocrine Tumor Diagnosis"],"prefix":"10.1016","volume":"18","author":[{"given":"Asha","family":"Kandathil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rathan M.","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cpet.2022.11.001_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaoncol.2019.4568","article-title":"Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in incidence","volume":"6","author":"Chauhan","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2022.11.001_bib2","first-page":"471","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.001_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.001_bib4","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1530\/ERC-12-0024","article-title":"Neuroendocrine tumor disease: an evolving landscape","volume":"19","author":"Frilling","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"10.1016\/j.cpet.2022.11.001_bib5","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2967\/jnumed.116.179234","article-title":"Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions","volume":"57","author":"Deroose","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.001_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2214\/AJR.18.19881","article-title":"Neuroendocrine tumor diagnosis and management: (68)Ga-DOTATATE PET\/CT","volume":"211","author":"Sanli","year":"2018","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.001_bib7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","article-title":"Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization","volume":"12","author":"Panzuto","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"10.1016\/j.cpet.2022.11.001_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.cpet.2022.11.001_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.001_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/flgastro-2020-101431","article-title":"Neuroendocrine tumours: what gastroenterologists need to know","volume":"13","author":"Khan","year":"2022","journal-title":"Frontline Gastroenterol"},{"issue":"10","key":"10.1016\/j.cpet.2022.11.001_bib11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1369\/0022155419856900","article-title":"Immunohistochemical expression of somatostatin receptor subtypes in a panel of neuroendocrine neoplasias","volume":"67","author":"Remes","year":"2019","journal-title":"J\u00a0Histochem Cytochem"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.001_bib12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s11307-019-01328-3","article-title":"The correlation between [(68)Ga]DOTATATE PET\/CT and cell proliferation in patients with GEP-NENs","volume":"21","author":"Yu","year":"2019","journal-title":"Mol Imaging Biol"},{"issue":"12","key":"10.1016\/j.cpet.2022.11.001_bib13","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/RLU.0000000000002309","article-title":"ACR practice parameter for the performance of gallium-68 DOTATATE PET\/CT for neuroendocrine tumors","volume":"43","author":"Subramaniam","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.001_bib14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2022.11.001_bib15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00259-006-0317-x","article-title":"Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?","volume":"34","author":"Antunes","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.001_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur J Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.001_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2967\/jnumed.116.180430","article-title":"Head-to-Head comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET\/CT: a prospective study of 59 patients with neuroendocrine tumors","volume":"58","author":"Johnbeck","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.001_bib18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00259-018-4117-x","article-title":"Influence of lanreotide on uptake of (68)Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation","volume":"46","author":"Aalbersberg","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.001_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4274\/mirt.galenos.2021.37268","article-title":"Physiological biodistribution of (68)Ga-DOTA-TATE in normal subjects","volume":"30","author":"Ozguven","year":"2021","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"10","key":"10.1016\/j.cpet.2022.11.001_bib20","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2967\/jnumed.120.251512","article-title":"Somatostatin receptor imaging and theranostics: current practice and future prospects","volume":"62","author":"Park","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.001_bib21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1148\/rg.352140164","article-title":"Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation","volume":"35","author":"Hofman","year":"2015","journal-title":"Radiographics"},{"issue":"12","key":"10.1016\/j.cpet.2022.11.001_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11912-021-01139-2","article-title":"New directions in imaging neuroendocrine neoplasms","volume":"23","author":"Refardt","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.001_bib23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00428-002-0609-x","article-title":"Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis","volume":"440","author":"Papotti","year":"2002","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.001_bib24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1210\/jc.2016-3445","article-title":"Localization of insulinoma using 68Ga-DOTATATE PET\/CT scan","volume":"102","author":"Nockel","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.001_bib25","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s00330-016-4475-3","article-title":"The added value of (68)Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin","volume":"27","author":"Kazmierczak","year":"2017","journal-title":"Eur Radiol"},{"issue":"8","key":"10.1016\/j.cpet.2022.11.001_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/diagnostics10080598","article-title":"Somatostatin receptor PET\/CT imaging for the detection and staging of pancreatic NET: a systematic review and meta-analysis","volume":"10","author":"Bauckneht","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.001_bib27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jamcollsurg.2015.04.005","article-title":"Results of (68)Gallium-DOTATATE PET\/CT scanning in patients with multiple endocrine neoplasia type 1","volume":"221","author":"Sadowski","year":"2015","journal-title":"J\u00a0Am Coll Surg"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.001_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12902-020-0525-6","article-title":"Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014","volume":"20","author":"Trikalinos","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.001_bib29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch"},{"issue":"12","key":"10.1016\/j.cpet.2022.11.001_bib30","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1097\/MD.0000000000000660","article-title":"TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution","volume":"94","author":"Yang","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.cpet.2022.11.001_bib31","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ejrad.2015.06.024","article-title":"Clinical value of (6)(8)Ga-DOTATATE-PET\/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET)","volume":"84","author":"Albanus","year":"2015","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.001_bib32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1245\/s10434-014-3981-2","article-title":"Impact of (68)Ga-DOTATATE PET\/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum","volume":"22","author":"Ilhan","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.001_bib33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","article-title":"The Impact of 68Ga-DOTATATE PET\/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom","volume":"57","author":"Skoura","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.001_bib34","doi-asserted-by":"crossref","first-page":"IJE04","DOI":"10.2217\/ije-2017-0005","article-title":"68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor","volume":"5","author":"Shell","year":"2018","journal-title":"Int J Endocr Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.001_bib35","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MPA.0000000000001791","article-title":"Recurrence patterns after surgical resection of gastroenteropancreatic neuroendocrine tumors: analysis from the national comprehensive cancer network oncology outcomes database","volume":"50","author":"Chan","year":"2021","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.001_bib36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jamaoncol.2018.0024","article-title":"Recurrence in resected gastroenteropancreatic neuroendocrine tumors","volume":"4","author":"Singh","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.001_bib37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1148\/radiol.13122501","article-title":"Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET\/CT","volume":"270","author":"Haug","year":"2014","journal-title":"Radiology"},{"issue":"40","key":"10.1016\/j.cpet.2022.11.001_bib38","doi-asserted-by":"crossref","first-page":"e1281","DOI":"10.1097\/MD.0000000000001281","article-title":"Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors","volume":"94","author":"Mehta","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.001_bib39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2217\/fon-2017-0393","article-title":"The utility of (68)Ga-DOTATATE positron-emission tomography\/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors","volume":"14","author":"Tirosh","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.cpet.2022.11.001_bib40","doi-asserted-by":"crossref","first-page":"679000","DOI":"10.3389\/fendo.2021.679000","article-title":"Role of somatostatin receptor in pancreatic neuroendocrine tumor development, diagnosis, and therapy","volume":"12","author":"Hu","year":"2021","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.001_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1634\/theoncologist.2020-0165","article-title":"68) Ga-DOTATATE Positron emission tomography-computed tomography quantification predicts response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors","volume":"26","author":"Lee","year":"2021","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.001_bib42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.119.240911","article-title":"NANETS\/SNMMI consensus statement on patient selection and appropriate use of (177)Lu-DOTATATE peptide receptor radionuclide therapy","volume":"61","author":"Hope","year":"2020","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2022.11.001_bib43","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.radonc.2019.09.003","article-title":"68)Ga-DOTATATE PET\/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours","volume":"141","author":"Sharma","year":"2019","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.001_bib44","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00259-019-04439-9","article-title":"Prognostic significance of somatostatin receptor heterogeneity in progressive neuroendocrine tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE","volume":"47","author":"Graf","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.001_bib45","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/cancers14030592","article-title":"Predictive and prognostic role of pre-therapy and interim 68Ga-DOTATOC PET\/CT parameters in metastatic advanced neuroendocrine tumor patients treated with PRRT","volume":"14","author":"Durmo","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859822000888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859822000888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:10:07Z","timestamp":1761563407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859822000888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1556859822000888"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2022.11.001","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastroenteropancreatic Neuroendocrine Tumor Diagnosis","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2022.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}